Clinical Trial Feasibility Intelligence

The Zonra model
identifies where
enrollment fails
before it does.

Zonra applies a proprietary feasibility framework to rare and genetic disease programmes, giving sponsors the intelligence to act on site strategy, patient identification, and geographic scope before any spend is committed.

80%

of trials fail to meet
enrollment timelines

up to $8M

lost per day of
enrollment delay

55%

of trials terminated
due to poor enrollment

80% of trials fail to meet their enrollment timeline

55% of trials are terminated due to poor enrollment

Enrollment delays cost sponsors up to $8M per day

Rare diseases in children: 72% are genetic in origin

Gene therapy programmes in active development: 400 globally

In ultra-rare disease fewer than 1 in 2,000 patients are diagnosed

Fewer than 20% of candidate sites qualify for gene therapy programs

80% of trials fail to meet their enrollment timeline

55% of trials are terminated due to poor enrollment

Enrollment delays cost sponsors up to $8M per day

Rare diseases in children: 72% are genetic in origin

Gene therapy programmes in active development: 400 globally

In ultra-rare disease fewer than 1 in 2,000 patients are diagnosed

Fewer than 20% of candidate sites qualify for gene therapy programs

The Zonra framework

Four analytical layers.
One enrollment risk score.

Every programme runs through the same four-layer framework. The output is a scored risk profile with site-level recommendations, ready to act on.

Layer 01

Patient pool intelligence

Diagnosed and undiagnosed population estimates, genotype stratification, geographic clustering, and patient registry gap analysis. The model locates where patients are before site selection begins.

Layer 02

Site capability assessment

Gene therapy infrastructure readiness, long-term follow-up capacity, vector handling requirements, investigator experience scoring, and competing trial load. Sites are ranked globally.

Layer 03

Competitive landscape mapping

Active and planned trials competing for the same patient pool. Sponsor profiles, projected enrollment timelines, and patient access pressure modeled across each geography.

Layer 04

Enrollment Risk Index

A composite score synthesising all four layers, with site-level and region-level mitigation recommendations. A decision-ready intelligence document, not a research summary.

How it works

Access the intelligence
before the clock starts.

Programme scoping

Disease area, development stage, geography, and known constraints. The framework is calibrated to your programme, not applied as a template.

Framework analysis

All four layers run across your programme, drawing on epidemiological registries, published literature, proprietary site data, and competitive intelligence sources.

Intelligence delivery

A structured intelligence document with your Enrollment Risk Index, a scored site list, and mitigation recommendations. Followed by a live readout with your team.

Timeline

Three to four weeks from scope call to delivery, within pre-IND and pre-CRO engagement windows.

Zonra Feasibility Analysis

Standard engagement · 3 to 4 weeks

Patient pool intelligence model

Core

Site capability scoring, global

Core

Competitive landscape mapping

Core

Enrollment Risk Index with recommendations

Core

Africa site and patient mapping

Extended

LTFU infrastructure readiness module

Extended

Regulatory pathway brief, FDORA and diversity

Extended

The intelligence produced in each engagement contributes to the Zonra site and patient database, improving model accuracy across future programmes.

Begin an engagement

Extended capability

The Zonra model covers geographies that standard feasibility tools ignore.

Most feasibility databases are built on Western site networks. For sponsors whose programmes require diverse patient populations, or who are exploring sites beyond Europe and North America, the standard model has a structural gap.

Zonra's extended coverage includes Africa site and patient mapping — qualified investigator identification, site readiness assessment, and patient registry analysis across African geographies. Built on primary research, not inherited assumptions.

Discuss extended coverage

400+

gene therapy
programmes globally

55%

of trials terminated
for poor enrollment

20%

of sites qualify
for gene therapy

$8M

lost per day of
enrollment delay

Who engages Zonra

Programmes where the cost
of uncertainty is highest.

Pre-Series B biotechs

Gene therapy and rare disease developers approaching pivotal studies. The Zonra model validates enrollment feasibility before the programme is locked in.

Academic spinouts

Rare disease programmes moving from academic discovery into clinical development. Zonra provides the enrollment evidence base that IND submissions require.

Sponsors navigating diversity requirements

Programmes required to demonstrate diverse patient enrollment under FDORA or similar mandates. Zonra identifies qualified sites and patient populations in underrepresented geographies.

The Zonra model identifies where enrollment fails before it does.

Four analytical layers.One enrollment risk score.

Access the intelligencebefore the clock starts.

The Zonra model covers geographies that standard feasibility tools ignore.

Programmes where the costof uncertainty is highest.

Know beforeyou commit.

The Zonra model
identifies where
enrollment fails
before it does.

Four analytical layers.
One enrollment risk score.

Access the intelligence
before the clock starts.

Programmes where the cost
of uncertainty is highest.

Know before
you commit.